Pfizer shares rose approximately 1% in pre-market trading. The move followed an announcement from AstraZeneca and Ionis Pharmaceuticals regarding the late-stage trial failure of Wainua.
Wainua was being tested for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a rare and fatal heart condition. Pfizer currently markets the leading treatment for this condition, Vyndamax.
Vyndamax generated $5.4 billion in global revenue. This performance was recorded in 2024.
The trial failure removes a significant near-term competitive threat to this key revenue stream. The setback also helps Pfizer, Alnylam Pharma, and BridgeBio Pharma maintain dominance in the lucrative ATTR-CM market.